Paper39366294
Evolving therapeutic landscape of advanced biliary tract cancer: from chemotherapy to molecular targets.
Kehmann L and 5 others. ESMO Open, 2024. Cited by 17 papers, by iCite.
Cite this record
ConductScience Library. Evolving therapeutic landscape of advanced biliary tract cancer: from chemotherapy to molecular targets. Papers, record 39366294. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39366294
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Evolving therapeutic landscape of advanced biliary tract cancer: from chemotherapy to molecular targets.
- PubMed
Topics4
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Biliary Tract Neoplasms | Major topic |
| Molecular Targeted Therapy | Major topic |
| Humans | |
| Antineoplastic Agents |
Source PubMed
References109
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 24681130 | Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. | J Hepatol | 2014 | https://conductscience.org/library/papers/24681130 | PubMed |
| 2 | 32380538 | Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. | Blood Adv | 2020 | https://conductscience.org/library/papers/32380538 | PubMed |
| 3 | 29850653 | Landscape of Microsatellite Instability Across 39 Cancer Types. | JCO Precis Oncol | 2017 | https://conductscience.org/library/papers/29850653 | PubMed |
| 4 | 27829276 | Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency. | Chin Clin Oncol | 2016 | https://conductscience.org/library/papers/27829276 | PubMed |
| 5 | 37870536 | Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. | J Clin Oncol | 2024 | https://conductscience.org/library/papers/37870536 | PubMed |
| 6 | 31300360 | Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. | Lancet Gastroenterol Hepatol | 2019 | https://conductscience.org/library/papers/31300360 | PubMed |
| 7 | 34656226 | Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. | Lancet Oncol | 2021 | https://conductscience.org/library/papers/34656226 | PubMed |
| 8 | 32223935 | TRK inhibitors in TRK fusion-positive cancers. | Ann Oncol | 2019 | https://conductscience.org/library/papers/32223935 | PubMed |
| 9 | 26258846 | Genomic spectra of biliary tract cancer. | Nat Genet | 2015 | https://conductscience.org/library/papers/26258846 | PubMed |
| 10 | 24185513 | Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. | Nat Genet | 2013 | https://conductscience.org/library/papers/24185513 | PubMed |
| 11 | 25503476 | Determining the fate of hepatic cells by lineage tracing: facts and pitfalls. | Hepatology | 2015 | https://conductscience.org/library/papers/25503476 | PubMed |
| 12 | 32416072 | Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. | Lancet Oncol | 2020 | https://conductscience.org/library/papers/32416072 | PubMed |
| 13 | 22180306 | Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. | Oncologist | 2012 | https://conductscience.org/library/papers/22180306 | PubMed |
| 14 | 27095655 | Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). | Nat Rev Gastroenterol Hepatol | 2016 | https://conductscience.org/library/papers/27095655 | PubMed |
| 15 | 36497187 | FGFR Inhibitors in Cholangiocarcinoma-A Novel Yet Primary Approach: Where Do We Stand Now and Where to Head Next in Targeting This Axis? | Cells | 2022 | https://conductscience.org/library/papers/36497187 | PubMed |
| 16 | 38870977 | Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial. | Lancet Gastroenterol Hepatol | 2024 | https://conductscience.org/library/papers/38870977 | PubMed |
| 17 | 24309328 | BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. | Mod Pathol | 2014 | https://conductscience.org/library/papers/24309328 | PubMed |
| 18 | 30056163 | Mismatch Repair Protein Defects and Microsatellite Instability in Malignant Pleural Mesothelioma. | J Thorac Oncol | 2018 | https://conductscience.org/library/papers/30056163 | PubMed |
| 19 | 12063950 | Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. | Hepatogastroenterology | 2002 | https://conductscience.org/library/papers/12063950 | PubMed |
| 20 | 30882996 | Anatomical, histomorphological and molecular classification of cholangiocarcinoma. | Liver Int | 2019 | https://conductscience.org/library/papers/30882996 | PubMed |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42698384 | Next Generation Sequencing for the Differentiation of Benign and Malignant Biliary Strictures. | Liver Int | 2026 | https://conductscience.org/library/papers/42698384 | PubMed |
| 42514220 | Choosing the Platinum Partner in Advanced Biliary Tract Cancer: A Propensity Score-Matched Real-World Comparison of Gemcitabine Plus Carboplatin Versus Gemcitabine Plus Cisplatin. | Life (Basel) | 2026 | https://conductscience.org/library/papers/42514220 | PubMed |
| 42512329 | Association Between Cumulative Chemotherapy Exposure and Survival Outcomes in Advanced Biliary Tract Cancer. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42512329 | PubMed |
| 42157316 | Safety and efficacy of PD-1/PD-L1 inhibitors combined with albumin-bound paclitaxel and fluorouracil-based agents as second-line therapy in biliary tract cancers. | World J Surg Oncol | 2026 | https://conductscience.org/library/papers/42157316 | PubMed |
| 41897384 | Inhibition of Glutamate Dehydrogenase as a Potential Strategy to Modulate Intrahepatic Cholangiocarcinoma Cell Metabolism. | Biomolecules | 2026 | https://conductscience.org/library/papers/41897384 | PubMed |
| 41783112 | Health-related quality of life in biliary tract cancer clinical trials. The current state and future directions. | ESMO Gastrointest Oncol | 2026 | https://conductscience.org/library/papers/41783112 | PubMed |
| 41694497 | Twenty-year temporal trends, risk profiles, and prognostic value of clinicopathological features in gallbladder cancer following cholecystectomy. | World J Gastroenterol | 2026 | https://conductscience.org/library/papers/41694497 | PubMed |
| 41652428 | Circulating tumor DNA-guided early detection and minimal residual disease monitoring in pancreatic and biliary cancers: evidence, barriers, and opportunities. | World J Surg Oncol | 2026 | https://conductscience.org/library/papers/41652428 | PubMed |
| 41229525 | Real-world effectiveness of durvalumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin in advanced gallbladder cancer: a study using the TriNetX global network. | Ther Adv Med Oncol | 2025 | https://conductscience.org/library/papers/41229525 | PubMed |
| 41212690 | Effectiveness of Chemotherapy Plus Immunotherapy and Molecular Alterations in Advanced Biliary Tract Cancer: Real-World Evidence From a Single-Center Australian Cohort. | Cancer Control | 2025 | https://conductscience.org/library/papers/41212690 | PubMed |
| 41158219 | Primary signet-ring cell carcinoma of the bile duct: clinical characteristics, survival comparison with cholangiocarcinoma, and SEER-based prognostic nomograms. | Transl Cancer Res | 2025 | https://conductscience.org/library/papers/41158219 | PubMed |
| 40940908 | Immune-Checkpoint Inhibitors for Biliary Tract Cancer: Who Benefits and What Is Next? | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40940908 | PubMed |
| 40836103 | Novel Biopsy Gun Impacts Biopsy Sample Quality and Quantity. | Cardiovasc Intervent Radiol | 2025 | https://conductscience.org/library/papers/40836103 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BRAF | 673 | PubTator's text mining | https://conductscience.org/library/genes/673 | NCBI Gene |
| FGFR2 | 2263 | PubTator's text mining | https://conductscience.org/library/genes/2263 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39366294
GET https://conductscience.org/api/papers/v1/39366294/references?page=2